Antibody Therapeutics

Antibody Therapeutics, official journal of Chinese Antibody Society, published by Oxford University Press, has been accepted by Clarivate for indexing in the Emerging Sources Citation Index (ESCI). This means that all content published in the Journal will now be indexed in Web of Science, providing greater discoverability and dissemination of content for published authors. Antibody Therapeutics will have its first impact factor in 2025. This is another key milestone of the journal after its inclusion by other databases such as PuMed and Scopus (2023 CiteScore: 8.7). Click the link to explore more author benefits through https://lnkd.in/eP9nFpMa We are also welcoming therapeutic antibody related submission through https://lnkd.in/dMJjtiD #Antibody #Therapeutics #ESCI

Antibody Therapeutics (indexed by ESCI, PubMed & Scopus, 2023 CiteScore: 8.7), the official journal of Chinese Antibody Society published by Oxford University Press would like to highlight most cited articles published in 2023. The 1st article is entitled “Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5” contributed by Toshiaki Maruyama from Abwiz Bio Inc. Here, researchers reported engineering and characterization of SARS-CoV-2 therapeutic antibodies that neutralize all Omicron variants to date. Surrogate virus neutralization assay shows low ng/mL IC50 values and biolayer interferometry showed pM affinity. The use of a proprietary platform technology, STage-Enhanced Maturation, is detailed. Click the link for the free access of the full article https://lnkd.in/e2MFyey8 We are also welcoming therapeutic antibody related submission through https://lnkd.in/dMJjtiD #Antibody #Therapeutics

Antibody Therapeutics (indexed by ESCI, PubMed & Scopus, 2023 CiteScore: 8.7), the official journal of Chinese Antibody Society published by Oxford University Press would like to share a research article entitled “AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains”. The corresponding author is Cristina Moldovan Loomis, Ph.D. from Just - Evotec Biologics. Here, researchers described a novel, cost-effective and accelerated approach to therapeutic antibody discovery, that couples de novo human antibodies derived in silico with high-throughput screening technologies. The platform’s applicability is demonstrated here by the identification of a panel of humanoid antibodies that are effective and with high developability potential. Click the link for the free access of the full article https://lnkd.in/g2N_82TN We are also welcoming therapeutic antibody related submission through https://lnkd.in/dMJjtiD #Antibody #Therapeutics

Antibody Therapeutics (indexed in ESCI, 2023 CiteScore: 8.7), the official journal of Chinese Antibody Society published by Oxford University Press would like to share a research article entitled “FcRider: a recombinant Fc nanoparticle with endogenous adjuvant activities for hybrid immunization”. The corresponding author is Wenda Gao from ANTAGEN PHARMACEUTICALS, INC.. Active immunization (vaccination) induces long-lasting immunity with memory, which takes weeks to months to develop. Passive immunization (transfer of neutralizing antibodies) provides immediate protection, yet with high cost and effects being comparatively short-lived. No currently approved adjuvants are compatible with formulations to combine active and passive immunizations, not to mention their huge disparities in administration routes and dosage. To solve this, researchers engineered the Fc fragment of human IgG1 into a hexamer nanoparticle and expressed its afucosylated form in Fut8−/− CHO cells, naming it “FcRider”, which is highly soluble with long-term stability, easily produced at high levels equivalent to those of therapeutic antibodies, and is amenable to conventional antibody purification schemes. Click the link for the free access of the full article https://lnkd.in/gwfFBkCa We are also welcoming therapeutic antibody related submission through https://lnkd.in/dMJjtiD #Antibody #Therapeutics

Antibody Therapeutics (indexed by ESCI, PubMed & Scopus, 2023 CiteScore: 8.7), the official journal of Chinese Antibody Society published by Oxford University Press would like to share a research article entitled “The process using a synthetic library that generates multiple diverse human single domain antibodies”. The corresponding author is Mark Tornetta from Tavotek Biotherapeutics. Single domain antibodies (sdAbs) possess unique characteristics that make them highly effective for developing complex therapeutics. A fully synthetic phage display library can generate VHOs that bind to disease relevant antigen conformations. Here, researchers demonstrated how screening can identify distinct VHO activities that have been used to generate differentiated drug molecules in various bispecific and multispecific antibody formats. Click the link for the free access of the full article https://lnkd.in/gtZcnhKm We are also welcoming therapeutic antibody related submission through https://lnkd.in/dMJjtiD #Antibody #Therapeutics

Antibody Therapeutics, official journal of Chinese Antibody Society, published by Oxford University Press, has been indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). Here, we would like to highlight Top 10 most cited articles published in 2022. The 9th paper entitled “Productivity and quality improvement for a symmetric bispecific antibody through the application of intensified perfusion cell culture” was contributed by Gong Chen and Weichang Zhou from WuXi Biologics. Aggregation, fragmentation, and low yield are issues frequently found during the cell culture process of bispecific antibodies (bsAbs), whose inherent complexity likely plays a role in causing these issues. Here, researchers made a head-to-head comparison between fed-batch cell culture and intensified perfusion cell culture with a symmetric bsAb case, and suggested that intensified perfusion cell culture could be a better choice than traditional fed-batch especially for complex molecules like bsAbs. The article has been cited 10 times as of today. Click the link for the free access of the full text of the article: https://lnkd.in/gP5u8Qgx We are also welcoming therapeutic antibody related submission through https://lnkd.in/dMJjtiD #Antibody #Therapeutics #Top10

Congratulations to Elpiscience Biopharmaceuticals' team on publishing the new article in our journal! The title of excellent paper is "A pan-allelic human SIRPα-blocking antibody, ES004-B5, promotes tumor killing by enhancing macrophage phagocytosis and subsequently inducing an effective T-cell response". Open access to this paper at: https://lnkd.in/gytzuPB3

Congratulations to Dr. Mitchell Ho for receiving a 2024 Asian American Engineer of the Year Award from the Chinese Institute of Engineers / USA - Seattle! Dr. Ho is the Deputy Chief of the Laboratory of Molecular Biology at National Cancer Institute (NCI), and has pioneered studies on the development of cell surface glypicans as new cancer therapeutic targets, with a focus on the generation of antibody engineering-based immunotherapies. We are proud that Dr. Mitchell Ho is also the Editor-in-Chief of our journal, Antibody Therapeutics, the official the official journal of Chinese Antibody Society, published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7).

Antibody Therapeutics, official journal of Chinese Antibody Society, published by Oxford University Press, has been indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). Here, we would like to highlight Top 10 most cited articles published in 2022. The 8th paper entitled “Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer” was contributed by Dianwen Ju and Xuyao Zhang（章旭耀） from Fudan University. Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the paradigm in hematological malignancies treatment, driving an ever-expanding number of basic research and clinical trials of genetically engineering T cells to treat solid tumors. CAR T-cell therapies based on the antibodies targeting Mesothelin, CEA, EGFR, EGFR, MUC1, DLL3, and emerging novel targets provide promising efficacy for lung cancer patients. However, clinical application of CAR T-cell therapy against lung cancer remains limited on account of physical and immune barriers, antigen escape and heterogeneity, on-target off-tumor toxicity, and many other reasons. In this review, we systematically summarize the latest advances in CAR T-cell therapy in lung cancer, focusing on the CAR structure, target antigens, challenges, and corresponding new strategies. The article has been cited 10 times as of today. Click the link for the free access of the full text of the article: https://lnkd.in/dYhcnviP We are also welcoming therapeutic antibody related submission through https://lnkd.in/dMJjtiD #Antibody #Therapeutics #Top10

Antibody Therapeutics, official journal of Chinese Antibody Society, published by Oxford University Press, has been indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). Here, we would like to highlight Top 10 most cited articles published in 2022. The 7th paper entitled “Augmenting recombinant antibody production in HEK293E cells: optimizing transfection and culture parameters” was contributed by Samuel Ken-En Gan and Wei-Li Ling from A*STAR - Agency for Science, Technology and Research. Recombinant antibody production is crucial for antibody research and development. Systematically investigating transfection and culture parameters such as PEI/DNA concentrations, complexation time, volume, temperature, supplements, etc., researchers demonstrated a ~4-fold light chain alone production increase to 1032 μg and a 2.5-fold whole antibody production increase to 51 μg from 2 mL transfections. The article has been cited 12 times as of today. Click the link for the free access of the full text of the article: https://lnkd.in/dNHr6GwU We are also welcoming therapeutic antibody related submission through https://lnkd.in/dMJjtiD #Antibody #Therapeutics #Top10